Transurethral resection of the bladder and adjuvant chemoradiation can permit eradication of the tumor and micrometastases. Close monitoring by sequential cystoscopy and biopsy can achieve similar survival outcomes to radical cystectomy, and could avoid invasive treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McDougal, W. S. et al. Cancer of the bladder, ureter and renal pelvis. In Cancer: Principles and Practice of Oncology, 8th edn (Eds DeVita, V. T. Jr et al.) 1358–1384 (Lippincott/Williams and Wilkins, Philadelphia, 2008).
Shipley, W. U. et al. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histologic factors prognostic of improved survival. J. Urol. 134, 679–683 (1985).
Shipley, W. U. et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60, 62–67 (2002).
Zietman, A. L. et al. Selective bladder conservation using transurethral resection, chemotherapy and radiation: management and consequences of TA, T1 and Tis recurrence within the retained bladder. Urology 58, 380–385 (2001).
Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859–866 (2003).
Bassi, P. et al. Neo-adjuvant M-VAC of invasive bladder cancer: the GUONE multicenter phase III trial. Eur. Urol. 33 (Suppl. 1), 142 (1998).
Shipley, W. U. et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89–03. J. Clin. Oncol. 16, 3576–3583 (1998).
Hussain, M. et al. Combination cisplatin, 5-fluorouracil and radiation therapy in locally advanced unresectable or medically unfit bladder cancer patients. A Southwest Oncology Group Study. J. Urol. 165, 56–60 (2001).
Kaufman, D. S. et al. A phase I/II RTOG study (99–06) in patients with muscle-invading bladder cancer of transurethral surgery plus paclitaxel, cisplatin and twice daily irradiation followed by either selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology [doi:10.1016/j.urology.2008.09.036].
Coen, J. J. et al. Trimodality therapy in the management of muscle-invasive bladder cancer: a selective organ-sparing approach. In Textbook of Bladder Cancer (Eds Lerner, S. P. et al.) 569–577 (Taylor and Francis, Oxford, 2006).
Zietman, A. L. et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J. Urol. 170, 1772–1776 (2003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Heney, N., Kaufman, D. & Shipley, W. Selective bladder-preserving therapy for muscle-invasive cancer. Nat Rev Clin Oncol 6, 193–194 (2009). https://doi.org/10.1038/nrclinonc.2009.21
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.21
